City of Hope is at the forefront of biomedical innovation, unveiling a series of pioneering clinical investigations and scientific breakthroughs that have the potential to transform cancer treatment and improve patient outcomes. These endeavors include novel drug trials targeting some of the most aggressive cancers, cutting-edge diagnostic technologies, and profound discoveries into the mechanisms of immune system recovery post-treatment. Furthermore, they illuminate the impact of social determinants on cancer risk, providing a holistic view of cancer biology intersecting with environmental and societal factors.
One of the most compelling new clinical trials launched by City of Hope involves a nonsurgical treatment strategy for rectal cancer. This Phase 2 study investigates the efficacy of combining the FOLFOX chemotherapy regimen—consisting of fluorouracil, oxaliplatin, and leucovorin calcium—with immunotherapeutic agents botensilimab and balstilimab. Significantly, this combination is administered to patients with localized rectal adenocarcinoma who have not undergone surgery, aiming to evaluate whether this regimen can achieve tumor eradication without the need for conventional radiation or invasive surgery, which often result in long-term urinary and bowel dysfunction. This trial embodies a paradigm shift toward organ preservation and improved quality of life for patients confronting rectal cancer.
In parallel, City of Hope has initiated a Phase 1 trial exploring the use of triapine, an oral ribonucleotide reductase inhibitor, in conjunction with radiation therapy for patients with recurrent glioblastoma and astrocytoma. These malignancies represent some of the most intractable brain tumors, notorious for treatment resistance and poor prognosis. By inhibiting the enzyme critical for DNA synthesis, triapine disrupts tumor cell replication and potentially enhances radiosensitivity. The primary objective is dose-escalation to establish safety and tolerability, but investigators are also monitoring tumor response and symptom alleviation. Success in this trial could open new therapeutic avenues for a cancer type with limited options.
.adsslot_TOak45IQYv{ width:728px !important; height:90px !important; }
@media (max-width:1199px) { .adsslot_TOak45IQYv{ width:468px !important; height:60px !important; } }
@media (max-width:767px) { .adsslot_TOak45IQYv{ width:320px !important; height:50px !important; } }
ADVERTISEMENT
Advancing the frontier of diagnostic oncology, City of Hope researchers have developed a promising liquid biopsy for early gastric cancer detection. The innovation leverages exosome-derived microRNAs (miRNAs) as sensitive biomarkers retrievable from blood samples. Collaborating with institutions in high-incidence regions such as Japan and South Korea, the team applied machine learning algorithms to identify a signature panel of 10 miRNAs capable of detecting early-stage gastric cancer with 95% accuracy. This noninvasive approach, branded as DESTINEX, could revolutionize screening protocols, circumventing the limitations of current endoscopy-based methods by offering a less invasive, more accessible, and cost-effective option—particularly pertinent for populations where widespread endoscopic screening is impractical.
Immunological restoration post-cancer treatment is another critical domain illuminated by City of Hope’s research. Investigators have spotlighted a subset of hematopoietic stem cells characterized by low expression of the Kit receptor (Kit^lo HSC), which plays a pivotal role in rejuvenating thymic function and thereby enhancing T cell reconstitution after allogeneic hematopoietic cell transplantation—a common therapeutic procedure for hematological malignancies. Experimental murine models revealed that Kit^lo HSCs promote thymic recovery and boost adaptive immunity, even counteracting age-associated thymic decline, through complex genomic regulatory networks involving key transcription factors such as ZBTB1. These findings suggest that targeting or augmenting Kit^lo HSC populations could be transformative in improving immune resilience following cytotoxic therapies.
The intersection of social determinants and cancer epidemiology also emerges as a critical area of inquiry. A large-scale epidemiological analysis by City of Hope highlights how residential segregation correlates with an increased lung cancer incidence among Black Americans. Using data from over 71,000 individuals, the study identified that living in racially less segregated neighborhoods corresponded with a lower lung cancer risk. Factors such as menthol cigarette usage—a product disproportionately marketed to Black communities—and environmental air pollution were implicated as mediators. This research not only underscores the significance of structural racism in health disparities but also informs targeted public health interventions and policy reforms aimed at mitigating these inequities.
Beyond clinical and societal investigations, City of Hope is celebrating landmark recognition in diabetes research with faculty members receiving prestigious awards for their contributions to understanding metabolic diseases. These honors reflect the institution’s broad commitment to exploring the molecular underpinnings of diabetes and its intersections with cancer biology, thereby fostering interdisciplinary innovation.
The institution’s research ecosystem continues to thrive under substantial funding awards from federal agencies. Noteworthy grants include a $6.2 million NIH/NCI award supporting advances in natural killer cell biology, a $4.1 million project probing cellular stress pathways affecting pancreatic beta cells, and multimillion-dollar funds allocated to study immune cell development and epigenetic regulation within metabolic contexts. These investments underpin ongoing efforts to elucidate fundamental cellular mechanisms with translational potential.
Taken together, City of Hope’s multifaceted research portfolio demonstrates the power of integrating clinical trial innovation, biomarker discovery, immunology, epidemiology, and basic science. The institution’s work not only seeks to improve individual patient outcomes but also addresses broader public health challenges, aiming to make hope a tangible reality across diverse populations afflicted by cancer, diabetes, and other chronic diseases.
Subject of Research: Cancer treatment innovation, liquid biopsy diagnostics, immune system recovery, social determinants of lung cancer risk, diabetes and metabolism research.
Article Title: City of Hope Advances Cancer Care with Novel Clinical Trials, Diagnostic Innovations, and Insights into Immune Recovery and Health Disparities
News Publication Date: Not specified
Web References:
Rectal Cancer Trial: https://clinicaltrials.gov/study/NCT06780787
Glioblastoma Trial: https://clinicaltrials.gov/study/NCT06860594
Gastric Cancer Biomarker Study: https://jamanetwork.com/journals/jamasurgery/fullarticle/2837074
Immune Recovery Research: https://www.nature.com/articles/s41467-025-61125-1
Lung Cancer and Segregation Study: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2835843
References:
Selection of peer-reviewed journal articles linked above.
Image Credits: City of Hope
Tags: biomedical innovation 2025City of Hope cancer researchclinical trials for rectal cancercutting-edge diagnostic technologiesFOLFOX chemotherapy regimenholistic view of cancer biologyimmune system recovery post-treatmentimmunotherapy for cancer treatmentnonsurgical cancer treatment strategiesorgan preservation in cancer caresocial determinants of cancer risktumor eradication without surgery